Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Prior treatment

• Subject is planning or in use of other antihypertensive drugs or other drugs may affect blood pressure during the trial;
• Alcohol or drug abuse;

Other illness

• Diagnosed with secondary hypertension, suspected grade 3 hypertension, acute hypertension, or at risk when current antihypertensive therapy discontinued;
• Suffered by severe heart disease within 6 months;
• Suffered by severe cerebrovascular disease within 6 months;
• Suffered by severe or malignant retinopathy;
• Out of controlled diabetes;
• History of malignant tumor;
• History of mental disorder;

Other

• Pregnant, lactating women or subject is planning to pregnant within 6 months after the trial;
• Assessed by the investigators as unsuitable for participating in the study.

• Male or female of age ≥18 years;
• Diagnosed with mild-moderate essential hypertension;
• Participant has understood the study-required procedures, voluntarily signed informed consent.